[breadcrumb_custom]

Tag: NovoCure Limited

Stock Investing

What Is The Reason Behind Novocure (NVCR) Stock Increasing 67% Pre-Hours Session?

Following positive results from its research to treat malignancies, NovoCure Limited (NASDAQ: NVCR) shares jumped 67.57% to $118.19 on Thursday morning. Which NVCR study had fruitful outcomes? The LUNAR study showed a statistically significant and clinically significant increase in overall survival above conventional therapy alone, according to Novocure’s (NVCR) announcement today that the research fulfilled its primary goal. Novocure has been evaluating the safety and efficacy of Tumor Treating Fields (TTFields) in combination with conventional therapies for stage 4 non-small cell lung cancer (NSCLC) following progression during or after treatment with platinum-based therapy in the pivotal, open-label, randomized LUNAR study.